American Heart Journal
Volume 155, Issue 6 , Pages 1039-1046 , June 2008

Sustained coronary patency after fibrinolytic therapy as independent predictor of 10-year cardiac survival: Observations from the Antithrombotics in the Prevention of Reocclusion in COronary Thrombolysis (APRICOT) trial

  • Marc A. Brouwer, MD, PhD

      Affiliations

    • Heartcenter, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
    • ,
  • Peter C. Kievit, MD

      Affiliations

    • Heartcenter, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
    • ,
  • Hendrik-Jan Dieker, MD

      Affiliations

    • Heartcenter, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
    • ,
  • Gerrit Veen, MD, PhD

      Affiliations

    • VU University Medical Center, Amsterdam, The Netherlands
    • ,
  • Aart J. Karreman, MSc

      Affiliations

    • VU University Medical Center, Amsterdam, The Netherlands
    • ,
  • Freek W.A. Verheugt, MD, PhD

      Affiliations

    • Heartcenter, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
    • Corresponding Author InformationReprint requests: Freek W. A. Verheugt, MD, PhD, Heartcenter, 670 Department of Cardiology, Radboud University Nijmegen Medical Center, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands.

Received 24 July 2007 ,Accepted 15 January 2008.

References 

  1. Wilson SH, Bell MR, Rihal CS, et al. Infarct artery reocclusion after primary angioplasty, stent placement, and thrombolytic therapy for acute myocardial infarction. Am Heart J. 2001;141:704–710
  2. The GUSTO Angiographic Investigators . The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction.. N Engl J Med. 1993;329:1615–1622
  3. Gibson CM, Cannon CP, Piana RN, et al. Angiographic predictors of reocclusion after thrombolysis: results from the Thrombolysis in Myocardial Infarction (TIMI) 4 trial. J Am Coll Cardiol. 1995;25:582–589
  4. Verheugt FW, Meijer A, Lagrand WK, et al. Reocclusion: the flip side of coronary thrombolysis. J Am Coll Cardiol. 1996;27:766–773
  5. Meijer A, Verheugt FW, Werter CJ, et al. Aspirin versus coumadin in the prevention of reocclusion and recurrent ischemia after successful thrombolysis: a prospective placebo-controlled angiographic study. Results of the APRICOT Study. Circulation. 1993;87:1524–1530
  6. White HD, French JK, Hamer AW, et al. Frequent reocclusion of patent infarct-related arteries between 4 weeks and 1 year: effects of antiplatelet therapy. J Am Coll Cardiol. 1995;25:218–223
  7. Brouwer MA, van den Bergh PJ, Aengevaeren WR, et al. Aspirin plus coumarin versus aspirin alone in the prevention of reocclusion after fibrinolysis for acute myocardial infarction: results of the Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis (APRICOT)–2 Trial. Circulation. 2002;106:659–665
  8. Gibson CM, Karha J, Murphy SA, et al. Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the Thrombolysis in Myocardial Infarction trials. J Am Coll Cardiol. 2003;42:7–16
  9. Ohman EM, Califf RM, Topol EJ, et al. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. TAMI Study Group. Circulation. 1990;82:781–791
  10. Brouwer MA, Bohncke JR, Veen G, et al. Adverse long-term effects of reocclusion after coronary thrombolysis. J Am Coll Cardiol. 1995;26:1440–1444
  11. Bauters C, Delomez M, Van Belle E, et al. Angiographically documented late reocclusion after successful coronary angioplasty of an infarct-related lesion is a powerful predictor of long-term mortality. Circulation. 1999;99:2243–2250
  12. Meijer A, Verheugt FW, van Eenige MJ, et al. Left ventricular function at 3 months after successful thrombolysis. Impact of reocclusion without reinfarction on ejection fraction, regional function, and remodeling. Circulation. 1994;90:1706–1714
  13. White HD, Norris RM, Brown MA, et al. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation. 1987;76:44–51
  14. Sadanandan S, Buller C, Menon V, et al. The late open artery hypothesis—a decade later. Am Heart J. 2001;142:411–421
  15. Hochman JS, Lamas GA, Buller CE, et al. Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med. 2006;355:2395–2407
  16. ISIS-2 Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;2:349–360
  17. White HD, Cross DB, Elliott JM, et al. Long-term prognostic importance of patency of the infarct-related coronary artery after thrombolytic therapy for acute myocardial infarction. Circulation. 1994;89:61–67
  18. French JK, Hyde TA, Straznicky IT, et al. Relationship between corrected TIMI frame counts at three weeks and late survival after myocardial infarction. J Am Coll Cardiol. 2000;35:1516–1524
  19. Brodie BR, Stuckey TD, Kissling G, et al. Importance of infarct-related artery patency for recovery of left ventricular function and late survival after primary angioplasty for acute myocardial infarction. J Am Coll Cardiol. 1996;28:319–325
  20. Hudson MP, Granger CB, Topol EJ, et al. Early reinfarction after fibrinolysis: experience from the global utilization of streptokinase and tissue plasminogen activator (alteplase) for occluded coronary arteries (GUSTO I) and global use of strategies to open occluded coronary arteries (GUSTO III) trials. Circulation. 2001;104:1229–1235
  21. Nijland F, Kamp O, Verheugt FW, et al. Long-term implications of reocclusion on left ventricular size and function after successful thrombolysis for first anterior myocardial infarction. Circulation. 1997;95:111–117
  22. The ASSENT-3 Investigators . Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet. 2001;358:605–613
  23. Madsen JK, Grande P, Saunamaki K, et al. Danish multicenter randomized study of invasive versus conservative treatment in patients with inducible ischemia after thrombolysis in acute myocardial infarction (DANAMI). DANish trial in Acute Myocardial Infarction. Circulation. 1997;96:748–755
  24. Andreotti F, Testa L, Biondi-Zoccai GG, et al. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients. Eur Heart J. 2006;27:519–526
  25. Antman EM, Morrow DA, McCabe CH, et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med. 2006;354:1477–1488
  26. Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005;352:1179–1189
  27. The OASIS-6 trial group. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction. The OASIS-6 randomized trial. JAMA. 2006;295:1519–1530
  28. Kievit PC, Brouwer MA, Veen G, et al. High-grade infarct related stenosis after successful thrombolysis: strong predictor of reocclusion, but not of clinical reinfarction. Am Heart J. 2004;148:826–833
  29. Michels KB, Yusuf S. Does PTCA in acute myocardial infarction affect mortality and reinfarction rates? A quantitative overview (meta-analysis) of the randomized clinical trials. Circulation. 1995;91:476–485
  30. Alonso JJ, Gimeno F, Sanz O, et al. Effect of early posthrombolysis stenting versus conservative approach to STEAMI on one-year angiographic outcome. An angiographic substudy of the GRACIA-1 trial. Circulation. 2003;108:468
  31. Collet JP, Montalescot G, Le May M, et al. Percutaneous coronary intervention after fibrinolysis: a multiple meta-analyses approach according to the type of strategy. J Am Coll Cardiol. 2006;48:1326–1335
  32. Dzavik V, Buller CE, Lamas GA, et al. Randomized trial of percutaneous coronary intervention for subacute infarct-related coronary artery occlusion to achieve long-term patency and improve ventricular function: the Total Occlusion Study of Canada (TOSCA)–2 trial. Circulation. 2006;114:2449–2457

PII: S0002-8703(08)00054-9

doi: 10.1016/j.ahj.2008.01.008

American Heart Journal
Volume 155, Issue 6 , Pages 1039-1046 , June 2008

Article Tools

* Image Usage & Resolution